- Previous Close
48.49 - Open
45.64 - Bid 46.76 x 100
- Ask 46.87 x 100
- Day's Range
46.06 - 47.86 - 52 Week Range
9.60 - 48.70 - Volume
948,558 - Avg. Volume
612,796 - Market Cap (intraday)
2.874B - Beta (5Y Monthly) 2.22
- PE Ratio (TTM)
-- - EPS (TTM)
-2.51 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
51.43
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
www.kymeratx.comRecent News: KYMR
View More
Performance Overview: KYMR
Trailing total returns as of 7/17/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KYMR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KYMR
View MoreValuation Measures
Market Cap
2.98B
Enterprise Value
2.54B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
37.56
Price/Book (mrq)
4.18
Enterprise Value/Revenue
32.01
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-194.67%
Return on Assets (ttm)
-14.60%
Return on Equity (ttm)
-26.35%
Revenue (ttm)
79.41M
Net Income Avi to Common (ttm)
-154.59M
Diluted EPS (ttm)
-2.51
Balance Sheet and Cash Flow
Total Cash (mrq)
520.54M
Total Debt/Equity (mrq)
12.24%
Levered Free Cash Flow (ttm)
-110.17M
Research Analysis: KYMR
View MoreCompany Insights: KYMR
KYMR does not have Company Insights
Research Reports: KYMR
View MoreDaily – Vickers Top Buyers & Sellers for 11/07/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 01/17/2023
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 06/01/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 05/10/2022
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.